A potentially game-changing new vaccine for tuberculosis is set for a major clinical trials programme, thanks to $550 million in funding from philanthropic organisations t
With cases of drug-resistant tuberculosis on the rise again around the world, GSK has sparked hopes of a new treatment option after reporting phase 2a data with a novel antitubercular drug
GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious diseases that mainly impact lower-income countries.
A cloud-based tuberculosis screening programme for rural communities in India, developed by UK company Feedback, is being supported by a cash injection from online retail giant Amazon.
Flushed with the success of its COVID-19 vaccine, BioNTech has pressed the accelerator on the development of shots for other infectious diseases, and now plans to take malaria and tuberculo